Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Eric Hsi, MD, is the Section Head of Hematopathology and Medical Director of the automated hematology, flow cytometry, and immunohistochemistry laboratories in the Institute of Pathology and Laboratory Medicine.
He received his medical training and post-graduate training in pathology and hematopathology at the University of Michigan and is board-certified in anatomic pathology, clinical pathology, and hematopathology. His clinical interests involve leukemia and lymphoma diagnosis, immunophenotyping and molecular diagnostics related to these disorders. Dr. Hsi's research interests include diagnostic and biologic prognostic markers in hematologic malignancy, as well as development of new therapeutics. He currently conducts research sponsored by various government and industry sources.
Dr. Hsi is a recognized expert in lymphoma diagnosis and is the Lymphoma Pathology Cadre Leader for the Cancer and Leukemia Group B. He has published more than 120 peer-reviewed articles and numerous book chapters and is the editor of a hematopathology text book. He regularly participates as faculty in post-graduate educational courses at national meetings, serves on committees for the American Society of Clinical Pathology and College of American Pathologists, and serves on the editorial board of several journals.
hematopathology, immunophenotyping, molecular diagnostics
Awards & Honors
NIH R21 CA123006 Characterization of Methods for Preservation of Phosphoproteins in Fixed Tissues, Principal Investigator
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 6/25/2016, Dr. Hsi has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.